Your browser doesn't support javascript.
loading
Stigma towards opioid use disorder in primary care remain a barrier to integrating software-based measurement based care.
Dela Cruz, Adriane M; Karns-Wright, Tara; Kahalnik, Farra; Walker, Robrina; Lanham, Holly J; Potter, Jennifer Sharpe; Trivedi, Madhukar H.
Afiliación
  • Dela Cruz AM; Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
  • Karns-Wright T; Department of Psychiatry & Behavioral Sciences, UT Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA. wrightt3@uthscsa.edu.
  • Kahalnik F; Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
  • Walker R; The Emmes Company, 401 N Washington St, Rockville, MD, 20850, USA.
  • Lanham HJ; Department of Psychiatry & Behavioral Sciences, UT Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
  • Potter JS; Department of Psychiatry & Behavioral Sciences, UT Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
  • Trivedi MH; Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
BMC Psychiatry ; 23(1): 776, 2023 10 24.
Article en En | MEDLINE | ID: mdl-37875835
ABSTRACT

BACKGROUND:

Opioid use disorder (OUD) is a deadly illness that remains undertreated, despite effective pharmacological treatments. Barriers, such as stigma, treatment affordability, and a lack of training and prescribing within medical practices result in low access to treatment. Software-delivered measurement-based care (MBC) is one way to increase treatment access. MBC uses systematic patient symptom assessments to inform an algorithm to support clinicians at critical decision points.

METHOD:

Focus groups of faculty clinicians (N = 33) from 3 clinics were conducted to understand perceptions of OUD diagnosis and treatment and whether a computerized MBC model might assist with diagnosis and treatment. Themes from the transcribed focus groups were identified in two phases (1) content analysis focused on uncovering general themes; and (2) systematic coding and interpretation of the data.

RESULTS:

Analysis revealed six major themes utilized to develop the coding terms "distinguishing between chronic pain and OUD," "current practices with patients using prescribed or illicit opioids or other drugs," "attitudes and mindsets about providing screening or treatment for OUD in your practice," "perceived resources needed for treating OUD," "primary care physician role in patient care not specific to OUD," and "reactions to implementation of proposed clinical decision support tool."

CONCLUSION:

Results revealed that systemic and attitudinal barriers to screening, diagnosing, and treating OUD continue to persist. Providers tended to view the software-based MBC program favorably, indicating that it may be a solution to increasing accessibility to OUD treatment; however, further interventions to combat stigma would likely be needed prior to implementation of these programs. TRIAL REGISTRATION ClinicalTrials.gov; NCT04059016; 16 August 2019; retrospectively registered; https//clinicaltrials.gov/ct2/show/NCT04059016 .
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Límite: Humans Idioma: En Revista: BMC Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Buprenorfina / Trastornos Relacionados con Opioides Límite: Humans Idioma: En Revista: BMC Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos